our future workforce · • optimizing usage of purification steps • maximizing utilisation of...

Our future workforceFlemming Dahl, Senior Vice President and Head of Quality, Novo Nordisk

Chemical Engineer

22 years with Novo Nordisk

• Production chemist

• Department Manager, Purification Plant, Diabetes API, Product Supply

• Vice President, Diabetes API, Product Supply

• Senior Vice President, Biopharm, Product Supply

• Senior Vice President, Corporate Quality

• Head of Quality

Who am I…?

Head of Quality in Novo Nordisk

48 years

Danish

Married

5 Children [7-19]

Free time: soccer, cycling and my family

ISPE Nordic 17. Nov. 2016 2

The current situation at Novo Nordisk


-40% YTD

Novo Nordisk share price development in 2016

• a Danish-based global healthcare company

• 90 years of innovation and leadership in diabetes care

• Haemophilia, growth disorders and obesity.

Novo Nordisk at a glance

4

Novo Nordisk -Corporate Presentation

PRODUCTS MARKETED IN

180 COUNTRIES

80 DIFFERENT NATIONALITIES

WORKING IN NOVO NORDISK IN DENMARK

SUPPLIER OF MORE THAN

HALF OF THEWORLD’S INSULIN

26,800,000PEOPLE USE OUR PRODUCTS

AFFILIATES IN COUNTRIES

R&D CENTRESIN CHINA, DENMARK,

AND US

$16.3 BILLIONIN TOTAL REVENUE

$2.1 BILLIONR&D SPEND IN

2015

75

EMPLOYS APPROXIMATELY

41,000 PEOPLEDIABETES

OBESITY

GROWTH DISORDERS

HAEMOPHILIA


Globalpresence

REGIONAL HEADQUARTERS5 CHINA, PACIFIC, EUROPE, US AND IO

R&D CENTRES3CHINA, DENMARK, AND THE US

STRATEGICPRODUCTION SITESBRAZIL, CHINA, DENMARK, FRANCE, US 5

75NOVO NORDISK AFFILIATES

NOVO NORDISK MARKETS ITS PRODUCTS IN

COUNTRIES WORLDWIDE180DENMARK

GLOBAL HEADQUARTERS


It is all about the patients…

Children should not get diabetes in the future”

JENNIFER ANTHONYJennifer has type 1 diabetes and lives in India

“


The Novo Nordisk Way

Our ambition is to strengthen our leadership in diabetes.

We aspire to change possibilities in haemophilia and other serious chronic conditions.

Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.


The Triple Bottom Line is how we do business…

Financially responsible

- profitable in the long term

Socially responsible

- helping people live better lives

Environmentally responsible

- minimising negative impacts

CO2

wastepatients

employees

communitiesenergy

waterhow we earn money

how we spend money

short term profitability

long term profitability


How many of you know someone with diabetes ?


Diabetes – type 2

Type 2 diabetes develops when

the beta-cells in the pancreas

start to become inefficient and

produce too little insulin for the

body’s needs.

Insulin is a hormone that

controls blood sugar levels.

415MILLION PEOPLE LIVE WITH

DIABETES

JIM SHEEDERJim has type 2 diabetesand lives in the US


Diabetes – type 1

Type 1 diabetes develops when a

person’s pancreas stops producing

insulin altogether.

Without immediate treatment,

people living with type 1 diabetes

can die.

Children should not get diabetes in the future”

JENNIFER ANTHONYJennifer has type 1 diabetes and lives in India

“


Is obesity a disease?


Obesity

Obesity is an abnormal or

excessive accumulation of fat

that may impair health.

Obesity is generally defined at a

population level as a BMI* of 30

or over.

*Body Mass Index (BMI) is a measure of body composition. BMI is calculated by taking a person's weight and dividing by their height squared.

600 MILLION

PEOPLE LIVE WITH

OBESITY

EVE BROUTYEve lives in the USand has a BMI of 38


Diabetes and Obesity is a very competitive market…

Notes: Only companies with marketed products and global presence are includedSources: Competitive Intelligence, May 2016


What does it take to develop a drug? Cost? Time?


From idea to patient

Industry estimates that out of 10,000 ideas that begin in the lab, just 10 will ever reach the stage where they are tested on people. Out of that, one may reach the market.

The process normally takes 10 to 15 years from initial work in the lab until a product is launched on the market.

10,000 IDEAS

10WILL BE TESTED

ON PEOPLE

ONEMAY REACH THE MARKET


The journey: 10-15 years from idea to patient

Pre-project

Idea

Manufacturing

Research

Clin

ical tr

ials

Product

registratio

n

Data on safety

and effic

acy

Reaching

the m

arket

Preparing

for la

unch

Phase 4

trials

1 in 10,000 ideas make it to market. The average estimated development costs of a final drug is around USD 1.3 billion

RESEARCH DEVELOPMENT COMMERCIALISATION


Innovation is key…


Novo Nordisk has a rich pipeline

Source: Strategic R&D, data extracted on 09 September 2016

LAI: Long Acting InsulinT1D: Type one diabetesOG: Oral GLP-1

� Insulin� GLP-1 analogue� Obesity� NAD� Haemophilia� Growth Hormone

APPROVALCONFIRMATORYEXPLORATORY TRIALSPRE-CLINICAL

� LAI287� PI406� Semaglutide NASH� AM833� PYY 1562� G530S� Concizumab� sc N8-GP

� Faster Aspart� N9-GP

� OI338GT� Semaglutide obesity� Anti-IL-21 GLP-1 T1D

� OG217SC� Semaglutide� N8-GP� somapacitan

DISCOVERY

� Tresiba®

� Ryzodeg®

� Xultophy®

� Victoza®

� Saxenda®

LAUNCH


• Continuous improvements:

• Minimizing time used for not value adding activities

• Optimizing usage of purification steps

• Maximizing utilisation of pumps, vessels and equipment

• Optimizing cleaning procedures

• Result:

• Capacity optimized 250%

• Yield maximized with more than 50%

Innovation example:GLP-1/liraglutide/Victoza ®Engineering work is key to success


• Novo Nordisk is researching the holy grail – biological medicines in a tablet. It has been pursued for a 100 years – and we have failed a couple of times.

• Oral semaglutide is to be the first protein-based medicine in a tablet.

Innovation example:Biologics in a tablet


Critical talent at Novo Nordisk

• IT/Automation Engineers

• Mechanical/Chemical Engineers

• Health Economists

• Medical Doctors

• QA/IT Specialists

• Biostatisticians

Source: Novo Nordisk Quarterly Talent Brief, August 2016


AND….there is a global cry for engineers acrossindustrial sectors

Source: ManpowerGroup, 2015 Talent Shortage Survey


Why is it difficult to fill jobs?


TOP 5 KEY REASONS FOR DIFFICULTY FILLING JOBS

35% Lack of available applicants/no applicants

34% Lack of technical competencies (‘hard skills’)

22% Lack of experiences

17% Lack of workplace competencies (‘soft skills’)

13% Looking for more pay than offered

Source: ManpowerGroup, 2015 Talent Shortage Survey


Does this matter at all for Novo Nordisk?


0

1000

2000

3000

4000

5000

6000

7000

8000

9000

10000

Example:The lack of engineers in Denmark

Source: Engineer The Future, Prognosis for lack of engineers and candidates in natural sciences, May 2015

Note: Civil and Diploma Engineers

Novo Nordisk site Kalundborg.


½Source: Novo Nordisk Annual Report 2015


Ongoing expansions in Denmark


In the US, we are expanding our production capacity and we need engineers…

Diabetes API, Clayton USA


We need ISPE to…


• Bring political attention to the need for engineers

• Stimulate positive public discussion around the field of engineering and

• Lead by example: engineers are crucial in solving global challenges in a sustainable way

• Share modern complexities of hiring specialists, generalists and everybody in-between

• Build pride within our profession

We need ISPE:


Contact:E-mail: [email protected]: http://linkedin.com/in/fldahlwww.novonordisk.com


our future workforce · • optimizing usage of purification steps • maximizing utilisation of...

Documents